• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Galecto Inc.

    3/8/24 4:29:47 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    S-8 1 glto_s-8_030824.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 8, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    GALECTO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    37-1957007

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    75 State Street, Suite 100

    Boston, Massachusetts, 02109

    Ole Maaloes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (+45) 70 70 52 10

    (Address of Principal Executive Offices)

    Galecto, Inc. 2020 Equity Incentive Plan

     

    (Full Title of the Plans)

    The Corporation Trust Company

    c/o Galecto, Inc.

    1209 Orange Street

    Wilmington, DC 19801

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Edwin M. O’Connor

    Goodwin Procter LLP

    620 8th Avenue

    New York, NY 10018

    (212) 813-8800

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers 1,355,635 additional shares of the Registrant’s common stock, $0.00001 par value per share ("Common Stock"), under the Registrant’s 2020 Equity Incentive Plan.

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1.

    Plan Information.

    The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Item 2.

    Registrant Information and Employee Plan Annual Information.

    The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.

    Incorporation of Documents by Reference.

    The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the SEC:

     

    (a)

    The registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 8, 2024;

     

    (b)

    The registrant's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2023 (but only with respect to information specifically incorporated by reference into the registrant’s Annual Report on Form 10-K for the year ended December 31, 2022); and

     

     

    (c)

    The description of the registrant’s common stock contained in the registrant’s Registration Statement on Form 8-A (File No. 001-39655), filed by the registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 23, 2020, including any amendments or reports filed for the purpose of updating such description.

     

    All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 4.

    Description of Securities.

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

     


    Item 6.

    Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

     

    The registrant has adopted provisions in its certificate of incorporation and bylaws that limit or eliminate the personal liability of its directors to the fullest extent permitted by section 102 of the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to the registrant or its stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

     

    •

     

    any breach of the director’s duty of loyalty to the registrant or its stockholders;

     

    •

     

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

    •

     

    any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

     

    •

     

    any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

     

    In addition, the registrant’s bylaws provide that:

     

    •

     

    the registrant will indemnify its directors, officers and, in the discretion of the registrant’s board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

     

    •

     

    the registrant will advance expenses, including attorneys’ fees, to its directors and, in the discretion of the registrant’s board of directors, to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the registrant, subject to limited exceptions.

     

    The registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the registrant will indemnify each of its directors, certain of its executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. The registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and the registrant will indemnify its directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the registrant or in furtherance of its rights. Additionally, certain of the registrant’s directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, the registrant has agreed in the indemnification agreements that its obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

     

    The registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.

     

     


    Item 8.

    Exhibits.

    EXHIBIT INDEX

     

     

     

    Exhibit

    No.

    Description

    4.1

    Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on November 4, 2020 (File No. 001-39655)).

     

     

    4.2

    Amended and Restated By-laws (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on November 4, 2020 (File No. 001-39655)).

     

     

    5.1*

    Opinion of Goodwin Procter LLP.

     

     

    23.1*

    Consent of EY Godkendt Revisionspartnerselskab, Independent Registered Public Accounting Firm.

     

     

    23.2*

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on signature page to this registration statement).

     

     

    99.1*

    2020 Equity Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K, as filed with the Commission on March 8, 2024).

     

     

     

    107*

     

    Filing fee table.

     

    *

    Filed herewith.

     

    Item 9.

    Undertakings.

    (a)

    The registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Copenhagen, Denmark, on the 8th day of March, 2024.

     

     

    Galecto, Inc.

    Date: March 8, 2024

    By:

    /s/ Hans T. Schambye, M.D., Ph.D.

    Hans T. Schambye, M.D., Ph.D.

    Chief Executive Officer and President

     

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Hans T. Schambye and Jonathan Freve, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

     

     

     

     

    Name

    Title

    Date

     

     

     

    /s/ Hans T. Schambye, M.D., Ph.D.

    Hans T. Schambye, M.D., Ph.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    March 8, 2024

     

     

     

    /s/ Jonathan Freve

    Jonathan Freve

    Chief Financial Officer (Principal

    Financial Officer and Accounting Officer)

    March 8, 2024

     

     

     

    /s/ Carl Goldfischer, M.D

    Carl Goldfischer, M.D.

    Chairman

    March 8, 2024

     

     

     

    /s/ Jayson Dallas, M.D.

     

    Director

     

    March 8, 2024

    Jayson Dallas, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Chau Q. Khuong

    Chau Q. Khuong

    Director

    March 8, 2024

     

     

     

    /s/ Søren Møller, Ph.D.

    Søren Møller, Ph.D.

    Director

    March 8, 2024

     

     

     

    /s/ Amit D. Munshi

    Amit D. Munshi

    Director

    March 8, 2024

     

     

     

    /s/ Anne Prener, M.D., Ph.D.

    Anne Prener, M.D., Ph.D.

    Director

    March 8, 2024

     

     

     

    /s/ David Shapiro, M.D.

    David Shapiro, M.D.

    Director

    March 8, 2024

     


    Get the next $GLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    1/7/2026$46.00Outperform
    Leerink Partners
    12/1/2025$32.00Buy
    Guggenheim
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Sattarzadeh Sherwin was granted 190,376 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/26/26 9:04:44 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sattarzadeh Sherwin

    3 - Galecto, Inc. (0001800315) (Issuer)

    1/26/26 9:03:21 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Hewes L. Becker was granted 264,629 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/7/26 7:34:03 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    SEC Filings

    View All

    Galecto Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Galecto, Inc. (0001800315) (Filer)

    1/12/26 8:00:32 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - Galecto, Inc. (0001800315) (Filer)

    1/6/26 8:15:25 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Galecto Inc.

    S-8 - Galecto, Inc. (0001800315) (Filer)

    1/2/26 5:15:28 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the "Company" or "Galecto") (NASDAQ:GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company's common stock to one new employee (the "Inducement Grant") on December 15, 2025 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement material to this individual entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share equal to $3

    12/16/25 5:00:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on Galecto with a new price target

    Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

    8/6/21 10:59:40 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

    10/15/24 8:30:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    11/7/24 3:07:49 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Galecto Inc.

    SC 13G - Galecto, Inc. (0001800315) (Subject)

    11/7/24 2:55:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Financials

    Live finance-specific insights

    View All

    Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

    Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

    10/7/24 8:45:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

    Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

    11/8/22 6:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

    Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

    10/31/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care